EPS: As of FY2025 Q1, the actual value is USD 0.02.<h3>Segment Revenue</h3><ul><li>Raphael Pharmaceutical Inc. did not generate any revenue during the three months ended March 31, 2025, and March 31, 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Research and Development Expenses: $72,000 for the three months ended March 31, 2025, a decrease of $307,000 or 81% compared to $379,000 for the same period in 2024.</li><li>General and Administrative Expenses: $353,000 for the three months ended March 31, 2025, an increase of $185,000 or 110% compared to $168,000 for the same period in 2024.</li><li>Operating Loss: $425,000 for the three months ended March 31, 2025, a decrease of $122,000 or 22% compared to $547,000 for the same period in 2024.</li><li>Net Loss: $429,000 for the three months ended March 31, 2025, a decrease of $121,000 or 22% compared to $550,000 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: $209,000 for the three months ended March 31, 2025, compared to $172,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $240,000 for the three months ended March 31, 2025, compared to $230,000 for the same period in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Raphael Pharmaceutical Inc. plans to continue its research and development efforts, focusing on the discovery and clinical development of cannabinoid-based therapies for autoimmune diseases, including rheumatoid arthritis and asthma. The company aims to obtain FDA and other regulatory approvals for its product candidates and intends to enter into royalty agreements with GMP-approved manufacturers and distributors.</li><li>Non-Core Business: The company does not currently own or operate manufacturing facilities and plans to rely on third parties for manufacturing and commercialization of its products upon receiving regulatory approval.</li><li>Priority: Raphael Pharmaceutical Inc. anticipates requiring approximately $500,000 for research and development activities and $700,000 for capital expenditures over the next 12 months, primarily for clinical trials and general operating costs.</li></ul>

Raphael Pharmaceutical Inc. | 10-Q: FY2025 Q1 EPS: USD 0.02